Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases

BACKGROUND: Evidence regarding the risk of immunogenicity in patients with inflammatory bowel disease (IBD) who switched anti-tumor necrosis factor alpha (anti-TNFα) therapies to a subsequent anti-TNFα (either infliximab or adalimumab) is conflicting. We aimed to assess the risk of consecutive immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Henit, Ungar, Bella, Kopylov, Uri, Fischler, Tali Sharar, Biron, Irit Avni, Ollech, Jacob E., Goren, Idan, Matar, Manar, Perets, Tsachi Tsadok, Shamir, Raanan, Dotan, Iris, Amir, Shira, Assa, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785344/
https://www.ncbi.nlm.nih.gov/pubmed/35082920
http://dx.doi.org/10.1177/17562848211068659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785344/
https://www.ncbi.nlm.nih.gov/pubmed/35082920
http://dx.doi.org/10.1177/17562848211068659

Ejemplares similares